Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

About this update from Beam Therapeutics Inc.

[{"type":"image","alt":"Beam logo","displaySize":"","headline":null,"caption":"Beam logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":154,"url":"https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MVnQbWAEvrVhOJdyJ1L51Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNg--/https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb","width":300,"height":154},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MVnQbWAEvrVhOJdyJ1L51Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNg--/https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb","width":300,"height":154}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD.","length":592,"tagName":"p"},{"type":"text","content":"“The comprehensive analyses being presented at EHA2026 further underscore the potential of risto-cel to correct key drivers of sickle cell disease pathology,” said Amy Simon, M.D., chief medical officer of Beam. “The data continue to support the ability of risto-cel to restore red blood cell health and function, including improvements in sickling and rheologic parameters comparable to sickle cell trait, while also reinforcing the relationship between fetal hemoglobin induction and improved clinical outcomes in sickle cell disease. Together, these findings contribute to the growing body of evidence supporting risto-cel’s potential differentiated profile for patients living with severe sickle cell disease.”","length":714,"tagName":"p"},{"type":"text","content":"Details are as follows:","length":23,"tagName":"p"},{"type":"text","content":"Title: Ristoglogene Autogetemcel Treatment Restored Red Blood Cell Health and Function in Patients with Sickle Cell Disease, with Sickling and Rheo...

More updates from Beam Therapeutics Inc.